lintuzumab-ac225
actinium
['actimab-a', 'solid tumor', 'mds']
actinium presents data demonstrating actimab-a's potential use against solid tumors by selectively depleting immunosuppressive mdscs, a key component of the tumor microenvironment, at the #aacr annual meeting read the full news release here: $atnm #aacr23
Actinium is developing innovative targeted radioimmunotherapies for the treatment of advanced cancers. Currently investigating therapies in #AML #BMT $ATNM